Tag: alpha tau

[Alpha Tau in GlobeNewswire] Alpha Tau announces multiple corporate updates ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

JERUSALEM, Oct. 21, 2022 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today its participation in the upcoming 2022 Annual Meeting of the American Society for Radiation Oncology (“ASTRO”), being held October 23 – 25, 2022 in San Antonio, TX, where the Company will be at Booth #3719. Read...

Read More

[Alpha Tau in GlobeNewswire] Alpha Tau announces the acceptance in major peer-reviewed journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of two landmark pre-clinical studies demonstrating significant potential synergies between the Alpha DaRT treatment and standard-of-care immunotherapy, chemotherapy and anti-angiogenic therapy

JERUSALEM, Sept. 08, 2022 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”) (Nasdaq: DRTS and DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the acceptance of two landmark pre-clinical studies in major peer-reviewed journals, both demonstrating the significant potential synergies between Alpha DaRT therapy and standard-of-care solid tumor therapies used today. Read...

Read More

[Alpha Tau in GlobeNewswire] Alpha Tau appoints industry veteran Peter Melnyk as Chief Commercial Officer

JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company’s Board of Directors in order to assume the full-time position of Alpha Tau’s Chief Commercial Officer. Read...

Read More

Latest from Twitter